Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting

摘要

Data on real-world treatment patterns, clinical outcomes, and health care utilization and costs in patients with newly diagnosed multiple myeloma are limited. We performed a claims analysis of 3075 patients treated with first-line lenalidomide- and/or bortezomib-based regimens. Lenalidomide-containing versus non-lenalidomide-containing therapies resulted in longer treatment durations and time to next treatment; initially higher pharmacy costs were lower after 3 years.